Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print August 4, 2008
DOI: 10.2337/db08-0596

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db08-0596v1
57/11/2999    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lan, H.
Right arrow Articles by Davis, H. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lan, H.
Right arrow Articles by Davis, H. R.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Lack of FFAR1/GPR40 does not Protect Mice from High-Fat Diet-Induced Metabolic Disease

Hong Lan1, Lizbeth M. Hoos1, Li Liu1, Glen Tetzloff1, Weiwen Hu2, Susan J. Abbondanzo2, Galya Vassileva2, Eric L. Gustafson2, Joseph A. Hedrick1, and Harry R. Davis1

Departments of 1Cardiovascular and Metabolic Diseases and
2Discovery Technologies, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA

Objective—: FFAR1/GPR40 is a G protein-coupled receptor expressed predominantly in pancreatic islets mediating free fatty acid-induced insulin secretion. However, the physiological role of FFAR1 remains controversial. It was previously reported that FFAR1 knockout (KO or Ffar1-/-) mice were resistant to high-fat diet (HFD)-induced hyperinuslinemia, hyperglycemia, hypertriglyceridemia and hepatic steatosis. A more recent report suggested that although FFAR1 was necessary for fatty acid-induced insulin secretion in vivo, deletion of FFAR1 did not protect pancreatic islets against fatty acid-induced islet dysfunction. This study is designed to investigate FFAR1 function in vivo using a third line of independently generated Ffar1-/- mice in the C57BL/6 background.

Research Design and Methods—: We used CL-316,243, a β-3 adrenergic receptor agonist, to acutely elevate blood free fatty acids and study its effect on insulin secretion in vivo. Ffar1+/+ (WT) and Ffar1-/- (KO) mice were placed on two distinct HFDs in order to study their response to diet-induced obesity.

Results—: Insulin secretion was reduced by ~50% in Ffar1-/- mice, confirming that FFAR1 contributes significantly to fatty acid stimulation of insulin secretion in vivo. However, Ffar1+/+ and Ffar1-/- mice had similar weight, adiposity, and hyperinsulinemia on HFDs, and Ffar1-/- mice showed no improvement in glucose or insulin tolerance tests. In addition, HFD-induced comparable levels of lipid accumulation in livers of Ffar1+/+ and Ffar1-/- mice.

Conclusions—: FFAR1 is required for normal insulin secretion in response to fatty acids, however, Ffar1-/- mice are not protected from HFD-induced insulin resistance or hepatic steatosis.


Correspondence: hong.lan{at}spcorp.com

Key Words: FFAR1/GPR40 • insulin secretion • fatty acid • high-fat diet • metabolic homeostasis


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.